Product Image
Please see full prescribing and safety information, including boxed warning, for HALOPERIDOL vials.

Available in:

  • 5 mg per mL single-dose vials**
  • 50 mg per 10 mL multi-dose vials

Benefits:

  • AP Rated
  • Not made with natural rubber latex
  • **Preservative-free

HALOPERIDOL Injection, USP*

Brand Name Equivalent: HALDOL® (HALDOL is a registered trademark of Johnson & Johnson Corporation)
Therapeutic Category: Antipsychotic

PreventIV MeasuresTM Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021
Description Strength Fill
Volume
Concentration Container
Size
Closure Unit
of Sale
806-01 Amber Glass Vial 5 mg** 1 mL 5 mg per mL 2 mL 13 mm 10
823-10 Amber Glass Vial 50 mg 10 mL 5 mg per mL 10 mL 13 mm 1
**Preservative-free
WARNING:
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Haloperidol injection is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).